NeoGenomics Inc logo

NeoGenomics Inc(NEO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
5-STAR RATING
PASS
LAST CLOSE
$16.02
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NEO

11/13/2026: NEO (5-star) is currently NOT-A-BUY. Pass it for now.

NeoGenomics is a specialized provider of cancer-focused genetic and molecular testing services, catering to hospitals and biopharma clients. The company’s primary strengths include its deep clinical oncology expertise and an expanding portfolio of innovative tests like the RaDaR liquid biopsy. Its core growth story centers on the increasing adoption of personalized cancer therapies, which require high-complexity diagnostics. However, investors must monitor risks related to laboratory operational costs, regulatory changes, and intense competition from large-scale reference labs. The stock is generally suited for growth-oriented investors, though it carries high volatility, as the company works to balance rapid innovation with sustainable profitability and long-term shareholder value.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company operates in the high-growth oncology testing space with significant potential for market expansion.
Momentum investorMixed fitMomentum is highly conditional on sustained earnings growth and positive clinical trial news flow.
Value investorWeak fitThe stock often trades at premiums based on future growth expectations rather than current deep-value metrics.
Dividend investorWeak fitThe company reinvests all capital and does not pay a dividend.
Low-risk investorWeak fitThe stock exhibits significant price volatility linked to regulatory and competitive risks in the diagnostic sector.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock price is susceptible to sharp movements based on sector-wide diagnostic trends and company news.
Valuation riskMedium / highMarket expectations for growth are often baked into the price, leaving little room for operational misses.
Competition risk (Ref Lab and Genomic rivals)HighStrong competition from large reference labs and specialized genomic firms limits pricing power.
Business qualityMediumWhile the diagnostic franchise is strong, the company must consistently maintain high clinical standards.
Dividend incomeLow / noneInvestors should not expect income generation from this equity.
Execution riskMedium / highSuccess depends on the company's ability to scale testing volume while managing lab costs effectively.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.07B USD
Price to earnings Ratio -
1Y Target Price 23.4
Price to earnings Ratio -
1Y Target Price 23.4
Volume (30-day avg) 2.0M shares
Beta 1.83
52 Weeks Range 7.07 - 20.15
Updated Date 11/14/2026
52 Weeks Range 7.07 - 20.15
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.24

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 96.86%
Avg. Invested days 58
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NEO receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
NEO has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+10.1%) is partially offset by negative earnings growth (-37.2%), weak cash generation (FCF margin -3.0%), weak profitability (net margin -14.9%).

Financial Health Rating

★★★★★
NEO's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 21.2%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is NEO's strongest growth driver at +36.0% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+10.1%, solid) is also solid, while earnings growth (-37.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 116.6% and approximately 91.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.68% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 16.13%
First Light Asset Management, LLC 9.49%
First Trust Advisors L.P. 7.82%
Greenhouse Funds LLLP 6.63%
Vanguard Portfolio Management, LLC 6.23%

Unit Economics (Per $1K Revenue)

★★★★★
NEO generates approximately $388 of gross profit, $-91 of operating income, and $-30 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 2.03%

Quantitative Style Profile

★★★★★
NEO has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical ServicesDiagnostic testing services for oncology patients.This is the primary revenue engine providing recurring income from standard diagnostic tests.
Pharma ServicesClinical trial support and companion diagnostics.This segment offers higher-margin growth opportunities tied to the success of new cancer drugs.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-10-28
When After Market
Estimate -0.01
Actual 0.01

Profitability

Profit Margin -4.1%
Operating Margin (TTM) -5.48%

Management Effectiveness

Return on Assets (TTM) -1.96%
Return on Equity (TTM) -3.94%

Valuation

Trailing PE -
Forward PE 222.22
Enterprise Value 2.38B
Price to Sales(TTM) 2.63
Enterprise Value 2.38B
Price to Sales(TTM) 2.63
Enterprise Value to Revenue 3.02
Enterprise Value to EBITDA 73.79
Shares Outstanding 129.39M
Shares Floating 117.92M
Shares Outstanding 129.39M
Shares Floating 117.92M
Percent Insiders 2.68
Percent Institutions 116.58

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.